BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Nancy J. Hutson Purchases 5,000 Shares of Stock

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Director Nancy J. Hutson bought 5,000 shares of the stock in a transaction dated Monday, May 20th. The shares were bought at an average price of $6.38 per share, for a total transaction of $31,900.00. Following the completion of the acquisition, the director now owns 86,818 shares in the company, valued at $553,898.84. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

BioCryst Pharmaceuticals Trading Down 1.8 %

Shares of BCRX stock opened at $6.54 on Thursday. The firm has a fifty day moving average price of $5.02 and a 200 day moving average price of $5.48. The company has a market cap of $1.35 billion, a P/E ratio of -6.22 and a beta of 1.96. BioCryst Pharmaceuticals, Inc. has a 12 month low of $4.03 and a 12 month high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the prior year, the company earned ($0.28) EPS. The business’s revenue was up 34.9% on a year-over-year basis. On average, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Tidal Investments LLC acquired a new position in BioCryst Pharmaceuticals in the first quarter valued at $282,000. Redwood Investment Management LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at about $621,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of BioCryst Pharmaceuticals by 62.0% in the first quarter. Jacobs Levy Equity Management Inc. now owns 156,119 shares of the biotechnology company’s stock valued at $793,000 after buying an additional 59,722 shares during the last quarter. Kynam Capital Management LP raised its holdings in shares of BioCryst Pharmaceuticals by 41.9% in the first quarter. Kynam Capital Management LP now owns 6,527,491 shares of the biotechnology company’s stock valued at $33,160,000 after buying an additional 1,927,491 shares during the last quarter. Finally, Sarissa Capital Management LP raised its holdings in shares of BioCryst Pharmaceuticals by 9.4% in the first quarter. Sarissa Capital Management LP now owns 1,094,168 shares of the biotechnology company’s stock valued at $5,558,000 after buying an additional 94,168 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BCRX. JMP Securities boosted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 7th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $14.00.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.